Sarepta Therapeutics, Inc. Forecast, price target & analysts
Sarepta Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Sarepta Therapeutics, Inc. Classifications & Recommendation
Sarepta Therapeutics, Inc. Price Target
| Target Price | $20.40 |
| Price | $18.22 |
| Potential |
11.96%
register free of charge
|
| Number of Estimates | 27 |
|
27 Analysts have issued a price target Sarepta Therapeutics, Inc. 2027 .
The average Sarepta Therapeutics, Inc. target price is $20.40.
This is
11.96%
register free of charge
$39.90
118.99%
register free of charge
$5.05
72.28%
register free of charge
|
|
| A rating was issued by 33 analysts: 14 Analysts recommend Sarepta Therapeutics, Inc. to buy, 13 to hold and 6 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2027 of
11.96%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.20 | 1.88 |
| 15.58% | 14.57% | |
| EBITDA Margin | -22.28% | 23.86% |
| 292.22% | 207.07% | |
| Net Margin | -32.45% | 17.70% |
| 362.40% | 154.54% |
27 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2026 . The average Sarepta Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2026. The average Sarepta Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
26 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Sarepta Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -7.13 | 3.15 |
| 427.06% | 144.18% | |
| P/E | 5.79 | |
| EV/Sales | 1.06 |
26 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sarepta Therapeutics, Inc....
Current Sarepta Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Sep 28 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 16 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Mar 26 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 26 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Mar 19 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Sep 28 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Jul 09 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Jul 09 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 16 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Mar 26 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 26 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Mar 19 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
